about
Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice.3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one and pregabalin attenuate tactile allodynia in the mouse model of chronic constriction injury.Synthesis, antimicrobial and anticonvulsant screening of small library of tetrahydro-2H-thiopyran-4-yl based thiazoles and selenazoles.Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione.Development of an in-vivo active reversible butyrylcholinesterase inhibitor.GABA transporters as targets for new drugs.New investigational drugs for the treatment of neuropathic pain.Zucapsaicin for the treatment of neuropathic pain.Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.The anxiolytic-like activity of a novel N-cycloalkyl-N-benzoylpiperazine derivative.Influence of analgesic active 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one on the antioxidant status, glucose utilization and lipid accumulation in some in vitro and ex vivo assays.Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies.Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice.Antinociceptive properties of N-Mannich bases derived from 3-substituted pyrrolidine-2,5-dione in the formalin model of persistent pain in mice.Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents.Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain.Comparison of pro-amnesic efficacy of scopolamine, biperiden, and phencyclidine by using passive avoidance task in CD-1 mice.Effect of pregabalin on fear-based conditioned avoidance learning and spatial learning in a mouse model of scopolamine-induced amnesia.Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice.The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression.Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress - A model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies.Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain.Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties.Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495.Synthesis and pharmacological properties of new GABA uptake inhibitors.Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides.Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one.Phencyclidine and Scopolamine for Modeling Amnesia in Rodents: Direct Comparison with the Use of Barnes Maze Test and Contextual Fear Conditioning Test in Mice.Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice.Experimental drugs for neuropathic pain.Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of painEnhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrinsSynthesis and activity of di- or trisubstituted N -(phenoxyalkyl)- or N -{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous systemAntinociceptive activity of novel amide derivatives of imidazolidine-2,4-dione in a mouse model of acute painSynthesis and anticonvulsant activities of novel 2-(cyclopentylmethylene)hydrazinyl-1,3-thiazoles in mouse models of seizuresEffect of selected drugs on zinc accumulation in teeth of laboratory animalsThe potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice
P50
Q34488146-BB547196-441A-4620-8047-B33656664D18Q35170603-EBECC7DB-6547-45AE-9530-358C8B871376Q35637859-1FE24D93-5F5B-46C3-970A-9829E4249316Q36021675-B4BD252B-5DDA-4F4D-8724-E52EFAF1E033Q36568597-7B52DD3B-A858-44C5-9233-247E2B03A076Q37522451-4DFDA5E3-DD17-432D-90AC-CB890A069351Q37856289-54C37344-EFBD-463B-83FE-DAE7DC4CAB77Q38217614-7C559135-5697-4CFD-846A-3BF32A704AF6Q38244583-DEFCD378-F60B-4A66-A7B4-2F50F2BA14C4Q38417418-534CD1D2-4C82-4901-A24F-BFF1BEEDEBC4Q38684332-9E36966F-26EE-4218-ADA1-83EBA6FD1ECFQ39037121-4CF18E0D-6821-4E9B-9A9B-640AEBA8D780Q39308033-44B13C5C-F3B8-4DAF-9071-FCB5D182EE02Q41568885-5CE945EB-DBEA-41DE-9EC2-430D6008C08EQ41622937-0D36E924-6861-47FE-92CA-1E978AB151F7Q42359901-F8D630A7-E8D5-4C1C-9026-518AB40112E4Q42817278-71C6BC99-14DC-4D42-8B90-B981275E0595Q46382557-E2C15E5B-0BB1-41A5-BEB9-56A4E57B0940Q46442913-9A68D6FC-0A9F-46EF-B3F9-8EBC87F5848DQ46468534-4A5B7987-E0A0-4249-A93D-14254B2DE77FQ47308714-154FEDD8-FDB3-4448-BF1D-5D0CCC2D50E0Q47706309-7992FB0B-3B74-4B6D-A2ED-A37E50DEE6AFQ47746059-E21918BC-52C7-49BF-98BC-3919DF562C0DQ47821103-11770BF1-C50B-4B89-9AEC-F3419F18F47BQ47851923-5D62D173-AE23-420B-A763-D6DA5AAC4654Q48043470-16886346-0F94-4A8A-BD59-4CD0A4813A97Q48216780-D05DE696-1F4A-4D01-9ABE-A3DC1FB98C7AQ48232388-12055686-489E-40E4-A559-69BCEEF87F3EQ48264964-20617804-5EA0-490F-B584-D95CD72386B7Q51029442-6267E5F2-C571-49D6-9359-347028E868D1Q52571998-21A3EC14-A76E-49C9-9946-02A28D04C543Q53805920-A2C8E901-E817-4EE6-AE84-247980ED131CQ54979408-695BC7C9-A7CD-4CA9-90E4-D3156C783C32Q57158893-C383904C-1D20-4121-9F17-9FCFE6C4016BQ58577471-A3ABF4E2-6B0D-430B-9B39-0CD410E2A59BQ63382949-941DC101-000A-4AD7-BB10-9B0BD94913DFQ87319167-A24723CB-4145-4DDF-8317-CD52C02326B9Q89134556-06B334C6-B032-4DA0-9799-450480873842Q89152273-74966658-C9F6-4DC2-AAC3-008C2F395B03Q91141459-6FBE0A1D-2895-4341-B9E1-FE22FDCE911C
P50
description
Polish researcher
@en
Pools onderzoekster
@nl
cercetătoare poloneză
@ro
chercheuse polonaise
@fr
investigadora polaca
@es
investigadora polaca
@gl
investigadora polonesa
@ca
polnische Forscherin
@de
polska naukowiec
@pl
ricercatora polacca
@it
name
Kinga Sałat
@ast
Kinga Sałat
@ca
Kinga Sałat
@de
Kinga Sałat
@en
Kinga Sałat
@es
Kinga Sałat
@fr
Kinga Sałat
@ga
Kinga Sałat
@gl
Kinga Sałat
@it
Kinga Sałat
@nl
type
label
Kinga Sałat
@ast
Kinga Sałat
@ca
Kinga Sałat
@de
Kinga Sałat
@en
Kinga Sałat
@es
Kinga Sałat
@fr
Kinga Sałat
@ga
Kinga Sałat
@gl
Kinga Sałat
@it
Kinga Sałat
@nl
altLabel
Kinga Salat
@en
prefLabel
Kinga Sałat
@ast
Kinga Sałat
@ca
Kinga Sałat
@de
Kinga Sałat
@en
Kinga Sałat
@es
Kinga Sałat
@fr
Kinga Sałat
@ga
Kinga Sałat
@gl
Kinga Sałat
@it
Kinga Sałat
@nl
P214
P1153
6506614610
P1412
P1559
Kinga Sałat
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-0614-5393
P735
P7859
viaf-317135266